Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: 10-182-B Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer

 


10-182-B Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer


Trial Focus

Endocrine Cancer

Objective

         This is a clinical trial of investigational drug Cediranib alone or Cediranib and Lenalidomide together which will be administered orally.

IRB Protocol #

13-3050

Trial Status

Archived

Principle Investigator

BRYAN HAUGEN

Sponsor

P2C

Contact

ANGELA PLATA at -- or --

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. This study will have 2 different groups of research subjects like you. Group A: will be instructed to take Cediranib alone. You will receive a supply of Cediranib every 28 days while enrolled on this study. Group B: will take Cediranib and Lenalidomide orally. You will receive a supply of Cediranib and Lenalidomide every 28 days while enrolled in this study. This 4-week period of time (28 days) is called a cycle. Only one cycle of study drug will be provided to you each month. You will be seen before starting study drug treatment, day 1 of starting the study drug(s) and two weeks after starting study drug treatment. // Eligibility criteria include but are not limited to 18 years or older with refractory differentiated thyroid cancer.Eligibility criteria include but are not limited to 18 years or older with refractory differentiated thyroid cancer.